-
FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD
02 Jan 2025 23:40 GMT
… with previously treated advanced pancreatic adenocarcinoma or non–small cell lung … advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring an NRG1 gene fusion … ), in which patients with pancreatic adenocarcinoma (n = 30) achieved an overall …
-
FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma
02 Jan 2025 17:32 GMT
… -negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) for tumors … /GEJ with histologically confirmed adenocarcinoma, no previous systemic therapy for …
-
FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after…
30 Dec 2024 14:40 GMT
… advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 gene … cell lung cancer or pancreatic adenocarcinoma harboring a neuregulin 1 … neuregulin 1 fusion-positive pancreatic adenocarcinoma who had disease progression following …
-
FDA Approves Tevimbra Plus Chemo for Gastric, Gastroesophageal Junction Adenocarcinoma
27 Dec 2024 20:43 GMT
… -negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) whose tumors …
-
FDA Approves Tislelizumab/Chemo in Gastric/GEJ Adenocarcinoma
27 Dec 2024 18:55 GMT
… or gastroesophageal junction (GEJ) adenocarcinoma with PD-L1 tumor expression … gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double … advanced gastric or gastroesophageal junction adenocarcinoma. BeiGene, Ltd. October 17, …
-
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
02 Jan 2025 19:53 GMT
… (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults … decades, and non-cardia gastric adenocarcinoma is increasing in younger individuals … in gastroesophageal junction and gastric adenocarcinoma in 2194 patients. Ann Surg …
-
Do YOU live in Britain’s fattest town? Map reveals places with the highest obesity rates as ‘drastic measures needed’
02 Jan 2025 20:45 GMT
… 13 different cancers, which include:
Adenocarcinoma of the esophagus
Breast cancer …
-
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
02 Jan 2025 19:53 GMT
… , gastroesophageal junction cancer, and esophageal adenocarcinoma.1 However, nivolumab and hyaluronidase …
-
Protein Marker Used to Suppress Pro-Tumor Inflammation
02 Jan 2025 18:09 GMT
… to their patients. Pancreatic ductal adenocarcinoma (PDAC) is one of the … improve antitumor responses.
Pancreatic ductal adenocarcinoma (PDAC) is commonly driven by …
-
Cancer Therapies Approved by the FDA in December 2024
02 Jan 2025 17:07 GMT
… for Some with NSCLC, Pancreatic Adenocarcinoma
The FDA has approved Bizengri … to both NSCLC and pancreatic adenocarcinoma.
The eNRGy study evaluated Bizengri … metastatic NRG1 fusion-positive pancreatic adenocarcinoma whose disease had progressed after …
About
© 1995-2025